Summit Therapeutics Inc. — Form 8-K
Filed July 22, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Summit announced updated overall survival (OS) data from the global Phase III HARMONi trial of ivonescimab plus chemotherapy versus placebo plus chemotherapy in EGFR-mutated NSCLC patients previously treated with third-generation EGFR TKIs. The June 2026 data cut-off showed hazard ratio of 0.76 (95% CI: 0.62–0.98) in the full intention-to-treat population and western patient subgroup, with median OS of 16.8 months (ivonescimab + chemo) versus 14.0 months (placebo + chemo); western patient median follow-up improved from 9.2 months (April 2025 primary analysis) to 23.2 months. The BLA with FDA has a PDUFA goal date of November 14, 2026.
Why this rating
Statistically significant OS benefit in updated analysis (primary missed p=0.057; updated p=0.0332) improves BLA approval odds before Nov 2026 PDUFA date. For $2.5B-market-cap biotech, potential first-in-class approval in large lung cancer indication is material but not transformational absent approval. Consistent western/Asian results strengthen regulatory case.
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.